UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of May 2022
Commission File Number: 001-39365
Amryt Pharma plc
(Translation of registrant's name into English)
Dept 920a 196 High Road, Wood Green,
London, United Kingdom, N22 8HH
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
<!--
Exhibits
The following documents, which are attached as exhibit 1 and exhibit 2 hereto, is incorporated by reference herein.
-->
Exhibits
The following documents, which are attached as exhibits 99.1 and 99.2 hereto, are incorporated by reference herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | Amryt Pharma plc |
| | | (Registrant) |
| | | |
| | | |
| Date: June 1, 2022 | | /s/ Rory Nealon |
| | | Rory Nealon |
| | | Chief Financial Officer |
| | | |
